In 1980, two scientists at the University of Arizona built a better version of the hormone that turns skin brown. The chemist was Victor Hruby. The biologist was Mac Hadley. They were not chasing a beach tan. They were chasing skin cancer. The logic was clean: if you could darken pale skin before it ever met the sun, you could armor it against the ultraviolet light that mutates it. A tan, used as a vaccine. (Sawyer, Hruby, Hadley, PNAS 1980)
So they took the body's own tanning signal, a hormone called alpha-MSH, and rebuilt it. They swapped two of its amino acids, and the new molecule held its shape far longer and hit roughly 26 times harder than the natural version. They called the family melanotan. Over the next forty years, that single idea split into three completely different lives: a medicine that lets children walk in daylight, a drug that treats low sexual desire, and a gray-market vial that millions have injected to get tan. Same parent. Three fates.
To understand why one melanotan is a clinic drug and another is a back-alley one, you have to understand the one thing that decides everything about these molecules. Not the dose. The lock.